Neogen Corporation
NASDAQ:NEOGMedical - Diagnostics & Research
+$0.16 today
- Market cap
- $2.42B
- Beta
- 1.80
- P/E (TTM)
- -3.3
- EPS (TTM)
- -$2.80
Volume 1.79M
Average 2.53M
NEOG Depreciation & Amortization
Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.
Neogen CorporationNASDAQ: NEOG
Depreciation & Amortization · Q1 FY2027 · quarter ended Aug 2026
Depreciation & amortization growth accelerates
Q1 FY2027 depreciation & amortization of $29.1M rose 0.2% year over year, ahead of the -6.9% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 1.0% from the prior quarter. Over 3 fiscal years it compounded at +8.7% a year.
Context
- Depreciation & amortization amounted to 13.4% of revenue in FY2026, down 0.7 pp from a year earlier.
- Depreciation & amortization increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +0.2% holds above the trailing-twelve-month pace of -6.9%.
Sources:Income StatementText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the income statement
- Latest · FY2026
- 116.3M USD
- Year-over-year change
- -7.5%
- 4-year CAGR
- +48.2%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2026 | 2026-05-31 | 116.3M | -7.5% |
| FY2025 | 2025-05-31 | 125.67M | +3.7% |
| FY2024 | 2024-05-31 | 121.23M | +34.0% |
| FY2023 | 2023-05-31 | 90.47M | +274.9% |
| FY2022 | 2022-05-31 | 24.13M | — |
Depreciation & Amortization vs competitors
How NEOG compares with its peers on the latest reported figures
- NEOG's LTM Aug 2026 depreciation & amortization of $116.35M is the 5th highest of the 7 companies compared; the peer median is $300.23M.
- Its year-over-year change of -6.9% is the 5th highest of 7, against a peer median of +4.1%.
- Depreciation & amortization amounts to 13.2% of revenue for NEOG, versus a peer median of 4.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $6.72B | +45.9% | +14.3% | 10.1% | |
| LTM Sep 2026 | $517M | -22.8% | -0.1% | 10.0% | |
| LTM Jun 2026 | $483M | -0.6% | +1.6% | 5.1% | |
| LTM Sep 2026 | $117.46M | -16.2% | +9.1% | 2.5% | |
| LTM Aug 2026 | $116.35M | -6.9% | +8.7% | 13.2% | |
| LTM Mar 2026 | $50.58M | +19.3% | +11.7% | 3.4% | |
| LTM Sep 2026 | $48.82M | +8.8% | -4.1% | 4.4% | |
| Peer median (excluding NEOG) | $300.23M | +4.1% | +5.3% | 4.7% | |
Competitors are the stored peer set for NEOG. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2022 May 2022 | FY2023 May 2023 | FY2024 May 2024 | FY2025 May 2025 | FY2026 May 2026 |
|---|---|---|---|---|---|
| Revenue | 527.16M | 822.45M | 924.22M | 894.66M | 870.4M |
| Cost of Revenue | 284.15M | 416.49M | 461.59M | 473.29M | 461.9M |
| Gross Profit | 243.01M | 405.96M | 462.64M | 421.38M | 408.5M |
| Gross Margin | 46.1% | 49.4% | 50.1% | 47.1% | 46.9% |
| Research & Development | 17.05M | 26.04M | 22.48M | 21.09M | 18.4M |
| Selling, General & Admin | 167.35M | 342.4M | 382.76M | 401.97M | 411.7M |
| Operating Expenses | 184.4M | 368.44M | 385.21M | 411.96M | 430.1M |
| Depreciation & Amortization | 24.13M | 90.47M | 121.23M | 125.67M | 116.3M |
| EBITDA | 84.34M | 124.39M | 182.6M | (937.75M) | 164.9M |
| EBITDA Margin | 16.0% | 15.1% | 19.8% | -104.8% | 18.9% |
| Operating Income | 58.62M | 37.52M | 77.43M | 9.42M | (21.6M) |
| Operating Margin | 11.1% | 4.6% | 8.4% | 1.1% | -2.5% |
| Interest Income | 1.34M | 3.17M | 6.36M | 3.11M | 0 |
| Interest Expense | 72K | 55.96M | 73.39M | 71.62M | 57.6M |
| Other Income / Expenses | 1.59M | (59.56M) | (91.73M) | (1.14B) | 12.6M |
| Income Before Tax | 60.21M | (22.04M) | (14.31M) | (1.13B) | (9M) |
| Pre-Tax Margin | 11.4% | -2.7% | -1.5% | -126.7% | -1.0% |
| Income Tax Expense | 11.9M | 828K | (4.88M) | (41.07M) | (1.1M) |
| Net Income | 48.31M | (22.87M) | (9.42M) | (1.09B) | (7.9M) |
| Net Margin | 9.2% | -2.8% | -1.0% | -122.1% | -0.9% |
| EPS (Basic) | 0.45 | (0.12) | (0.04) | (5.03) | (0.04) |
| EPS (Diluted) | 0.45 | (0.12) | (0.04) | (5.03) | (0.04) |
| Weighted Avg Shares | 107.68M | 188.88M | 216.48M | 216.89M | 217.5M |
| Weighted Avg Shares (Diluted) | 108.02M | 188.88M | 216.48M | 216.89M | 217.5M |
Neogen Corporation
NASDAQ:NEOG
Intrinsic Alpha fair value
Locked
Current Price
$11.08
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.